Orchestra Biomed Holdings Stock Buy Hold or Sell Recommendation
| OBIO Stock | 5.77 0.33 6.07% |
Given the investment horizon of 90 days and your highly speculative risk level, our recommendation regarding Orchestra BioMed Holdings is 'Cautious Hold'. The recommendation algorithm takes into account all of Orchestra BioMed's available fundamental, technical, and predictive indicators you will find on this site.
Check out Orchestra BioMed Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as Orchestra and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Orchestra BioMed Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
Orchestra |
Execute Orchestra BioMed Buy or Sell Advice
The Orchestra recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Orchestra BioMed Holdings. Macroaxis does not own or have any residual interests in Orchestra BioMed Holdings or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Orchestra BioMed's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Orchestra BioMed Trading Alerts and Improvement Suggestions
| Orchestra BioMed generated a negative expected return over the last 90 days | |
| Orchestra BioMed has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 2.76 M. Net Loss for the year was (49.12 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Orchestra BioMed generates negative cash flow from operations | |
| About 22.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Pivots Trading Plans and Risk Controls - Stock Traders Daily |
Orchestra BioMed Returns Distribution Density
The distribution of Orchestra BioMed's historical returns is an attempt to chart the uncertainty of Orchestra BioMed's future price movements. The chart of the probability distribution of Orchestra BioMed daily returns describes the distribution of returns around its average expected value. We use Orchestra BioMed Holdings price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Orchestra BioMed returns is essential to provide solid investment advice for Orchestra BioMed.
| Mean Return | -0.12 | Value At Risk | -7.67 | Potential Upside | 7.24 | Standard Deviation | 5.00 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Orchestra BioMed historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Orchestra BioMed Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Orchestra BioMed or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Orchestra BioMed's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Orchestra stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.36 | |
β | Beta against Dow Jones | 2.40 | |
σ | Overall volatility | 4.92 | |
Ir | Information ratio | -0.05 |
Orchestra BioMed Volatility Alert
Orchestra BioMed Holdings exhibits very low volatility with skewness of -0.34 and kurtosis of 1.11. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Orchestra BioMed's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Orchestra BioMed's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Orchestra BioMed Fundamentals Vs Peers
Comparing Orchestra BioMed's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Orchestra BioMed's direct or indirect competition across all of the common fundamentals between Orchestra BioMed and the related equities. This way, we can detect undervalued stocks with similar characteristics as Orchestra BioMed or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Orchestra BioMed's fundamental indicators could also be used in its relative valuation, which is a method of valuing Orchestra BioMed by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Orchestra BioMed to competition |
| Fundamentals | Orchestra BioMed | Peer Average |
| Return On Equity | -0.92 | -0.31 |
| Return On Asset | -0.39 | -0.14 |
| Operating Margin | (16.56) % | (5.51) % |
| Current Valuation | 140.68 M | 16.62 B |
| Shares Outstanding | 37.82 M | 571.82 M |
| Shares Owned By Insiders | 22.14 % | 10.09 % |
| Shares Owned By Institutions | 54.97 % | 39.21 % |
| Number Of Shares Shorted | 778.62 K | 4.71 M |
| Price To Book | 4.45 X | 9.51 X |
| Price To Sales | 78.12 X | 11.42 X |
| Revenue | 2.76 M | 9.43 B |
| EBITDA | (51.22 M) | 3.9 B |
| Net Income | (49.12 M) | 570.98 M |
| Total Debt | 1.69 M | 5.32 B |
| Book Value Per Share | 1.22 X | 1.93 K |
| Cash Flow From Operations | (46.13 M) | 971.22 M |
| Short Ratio | 17.03 X | 4.00 X |
| Earnings Per Share | (1.60) X | 3.12 X |
| Target Price | 15.6 | |
| Number Of Employees | 56 | 18.84 K |
| Beta | 0.41 | -0.15 |
| Market Capitalization | 206.79 M | 19.03 B |
| Total Asset | 95.21 M | 29.47 B |
| Retained Earnings | (248.85 M) | 9.33 B |
| Working Capital | 77.91 M | 1.48 B |
| Net Asset | 95.21 M |
Note: Acquisition by David Hochman of 2500 shares of Orchestra BioMed at 4.91 subject to Rule 16b-3 [view details]
Orchestra BioMed Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Orchestra . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 2015.63 | |||
| Daily Balance Of Power | 0.9167 | |||
| Rate Of Daily Change | 1.06 | |||
| Day Median Price | 5.61 | |||
| Day Typical Price | 5.66 | |||
| Price Action Indicator | 0.32 | |||
| Period Momentum Indicator | 0.33 |
About Orchestra BioMed Buy or Sell Advice
When is the right time to buy or sell Orchestra BioMed Holdings? Buying financial instruments such as Orchestra Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Orchestra BioMed in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Macroaxis Index Thematic Idea Now
Macroaxis Index
An experimental equal-weighted index theme of selected equities generated based on Macroaxis rating and scoring system. The Macroaxis Index theme has 52 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Macroaxis Index Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Orchestra BioMed Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Orchestra BioMed. If investors know Orchestra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Orchestra BioMed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.60) | Revenue Per Share 0.073 | Quarterly Revenue Growth 1.356 | Return On Assets (0.39) | Return On Equity (0.92) |
The market value of Orchestra BioMed Holdings is measured differently than its book value, which is the value of Orchestra that is recorded on the company's balance sheet. Investors also form their own opinion of Orchestra BioMed's value that differs from its market value or its book value, called intrinsic value, which is Orchestra BioMed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Orchestra BioMed's market value can be influenced by many factors that don't directly affect Orchestra BioMed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Orchestra BioMed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Orchestra BioMed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Orchestra BioMed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.